Drugs / 2-mercaptoethane Sulphonate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00286403 | Aug → Oct 2008 | acute kidney injury | Southeast Renal Research Institute | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-mercaptoethane Sulphonate | “Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial” NCT00286403 ↗ |
| Known as | MESNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00286403 ↗ |
| Route | Intravenous | “combination of fenoldopam plus intravenous MESNA” NCT00286403 ↗ |